Our results show that treatment with recombinant uPA (Rh-uPA) protein increased osteosarcoma cell migration (HOS cells, 298.5% increase; 143B cells, 234.2% increase) and cell invasive ability (HOS cells, 220.2% increase; 143B cells, 204.1% increase), compared with shLuc-OS cells (Figure 4). The gene discussed is PLAU; the disease is osteosarcoma.